Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...

The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...

(Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer’s disease ...